Boston Scientific announces agreement to acquire Penumbra, Inc.
PR Newswire • • business
Key Points:
- Boston Scientific has entered a definitive agreement to acquire Penumbra for approximately $14.5 billion, paying $374 per share in a mix of cash (73%) and stock (27%), expanding its cardiovascular portfolio and entering mechanical thrombectomy and neurovascular markets.
- Penumbra specializes in innovative thrombectomy devices and neurovascular solutions targeting vascular diseases such as stroke, pulmonary embolism, and deep vein thrombosis, with expected 2025 revenue growth of around 17.3%-17.5% to $1.4 billion.
- The acquisition aims to leverage Penumbra's technologies to address the global prevalence of cardiovascular diseases, enhance Boston Scientific's revenue and margins, and broaden patient access to novel treatments worldwide.
- The transaction,
